Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years.

ABSTRACT:

Aims

Despite long clinical experience with deferiprone, there is limited information on its pharmacokinetics in children aged <6 years. Here we assess the impact of developmental growth on the pharmacokinetics of deferiprone in this population using a population approach. Based on pharmacokinetic bridging concepts, we also evaluate whether the recommended doses yield appropriate systemic exposure in this group of patients.

Methods

Data from a study in which 18 paediatric patients were enrolled were available for the purposes of this analysis. Patients were randomised to three deferiprone dose levels (8.3, 16.7 and 33.3 mg kg^-1 ). Blood samples were collected according to an optimised sampling scheme in which each patient contributed to a maximum of five samples. A

SUBMITTER: Bellanti F 

PROVIDER: S-EPMC5306498 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature